Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab in vulvar squamous cell carcinoma
NL-OMON59491Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in vulvar squamous cell carcinoma (VSCC), sponsored by Leiden University Medical Center. Primary endpoints: Clinical efficacy of neoadjuvant PD-1 blockade and CD4 positive CD39 positive PD-1 positive intratumoral effector T-cell response. Started May 2023; status: completed.
02
Drugs
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON59491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59491.